$1.24
0.81%
Nasdaq, Sep 25, 04:00 pm EDT. Closed.
ISIN
US81362J1007
Symbol
VANI

Second Sight Medical Products, Inc. Stock price

$1.24
-0.18 12.68% 1M
+0.11 9.73% 6M
+0.01 0.81% YTD
-0.19 13.29% 1Y
+0.30 31.91% 3Y
-9.02 87.91% 5Y
-76.76 98.41% 10Y
-478.04 99.74% 20Y
Nasdaq, Closing price Fri, Sep 25 2026
+0.01 0.81%

Is Second Sight Medical Products, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$111.9m
Enterprise Value
$92.0m
Net debt
positive
Cash
$19.9m
Shares outstanding
89.4m
Valuation (TTM | estimate)
P/E
negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
5.9
Financial Health
Equity Ratio
39.9%
Return on Equity
-
ROCE
-77.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-26.8m
EBIT
$-27.2m
Net Income
$-26.3m
Free Cash Flow
$-26.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-1.4%
EBIT
-1.6%
Net Income
-3.0%
Free Cash Flow
-14.5%
Margin
Gross
-
EBITDA
-
EBIT
-
Net
-
Free Cash Flow
-
More
EPS
$-0.3
FCF per Share
$-0.3
Short interest
1.5%
Employees
42
Rev per Employee
-

Second Sight Medical Products, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Second Sight Medical Products, Inc. forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Second Sight Medical Products, Inc. forecast:

Buy
90%
Hold
10%

Financial data from Second Sight Medical Products, Inc.

Jun '26
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.23 9.23
1% 1%
-
- Research and Development Expense 18 18
3% 3%
-
-27 -27
1% 1%
-
- Depreciation and Amortization 0.48 0.48
20% 20%
-
EBIT (Operating Income) EBIT -27 -27
2% 2%
-
Net Profit -26 -26
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Second Sight Medical Products, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Second Sight Medical Products, Inc. Stock News

Neutral
GlobeNewsWire
●
about one month ago
All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management; top-line data expected in November 2026 Company entered into non-exclusive agreement with Novo Nordisk to evaluate NPM-139 and Vivani's proprietary NanoPortal™ technology Completion of the Cortigent-ClearOne merg...
Neutral
GlobeNewsWire
●
about 2 months ago
Dosing of the first participant commenced ahead of schedule and was rapidly followed by initial dosing in all trial participants.
Neutral
CNBC
●
3 months ago
Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss. The biotech company is in the early stages of developing an experimental implant of semaglutide, the active ingredient in Novo Nordisk's obesity injection Wegovy and diabetes counterpart Ozempic.
More Second Sight Medical Products, Inc. News

Company Profile

Second Sight Medical Products, Inc. engages in the development, manufacture, and marketing of implantable visual prosthetics. It operates through the following geographical segments: United States, Italy, France, and China. The firm's product include Argus II Retinal Prosthesis System that treats outer retinal degenerations, such as retinitis pigmentosa, also referred to as RP. The company was founded by Alfred E. Mann, Aaron Mendelsohn, Sam Williams, Robert J. Greenberg, and Gunnar Bjorg in 1998 and is headquartered in Sylmar, CA.

Head office United States
CEO Dr. Mendelsohn
Employees 42
Founded 2003
Website vivani.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today